专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007143081A3 THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES 审中-公开
标题翻译：用于治疗淋巴细胞恶性肿瘤的治疗药物
公开(公告)号：WO2007143081A3
公开(公告)日：2008-02-21
申请号：PCT/US2007012921
申请日：2007-06-01
申请人： UNIV OHIO STATE RES FOUND , BYRD JOHN C , PERROTTI DANILO , CHEN CHING-SHIH , DALTON JAMES T , FRISSORA FRANK , ZHAO XIAOBIN , LIU QING , MUTHUSAMY NATARAJAN
发明人： BYRD JOHN C , PERROTTI DANILO , CHEN CHING-SHIH , DALTON JAMES T , FRISSORA FRANK , ZHAO XIAOBIN , LIU QING , MUTHUSAMY NATARAJAN
IPC分类号： A61K31/135
CPC分类号： A61K31/137 , A61K45/06
摘要： Methods- for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4- octylphenyl) ethyl] propane 1, 3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
摘要翻译：方法 - 用于治疗和预防淋巴恶性肿瘤，包括但不限于急性淋巴细胞性白血病（ALL），慢性淋巴细胞白血病（CLL），B细胞淋巴瘤，急性骨髓性白血病（AML）和套细胞淋巴瘤（MCL）。所述方法包括将治疗有效量的FTY720（2-氨基-2- [2-（4-辛基苯基）乙基]丙烷-1,3-二醇盐酸盐）或其衍生物，药学上可接受的盐或其前药给予课程。

2. 发明申请

WO2006102611A2 THERAPEUTIC AGENTS FOR THE TREATMENT OF LEUKEMIA 审中-公开
标题翻译：治疗白血病的治疗药物
公开(公告)号：WO2006102611A2
公开(公告)日：2006-09-28
申请号：PCT/US2006010882
申请日：2006-03-24
申请人： UNIV OHIO STATE RES FOUND , PEROTTI DANILO , NEVIANI PAOLO , SANTHANAM RAMASAMY , BYRD JOHN C , MARCUCCI GUIDO , MUTHUSAMY NATARAJAN , CHEN CHING-SHIH
发明人： PEROTTI DANILO , NEVIANI PAOLO , SANTHANAM RAMASAMY , BYRD JOHN C , MARCUCCI GUIDO , MUTHUSAMY NATARAJAN , CHEN CHING-SHIH
IPC分类号： A61K31/353
CPC分类号： A61K31/353 , C12Q1/42 , G01N2500/10
摘要： The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph' -ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
摘要翻译：本发明提供了治疗具有BCR / ABL介导的白血病（包括慢性骨髓性白血病（CML））的哺乳动物的方法，特别是CML的爆发危机阶段，费城阳性急性淋巴细胞白血病（Ph'-ALL）和难治性白血病。本发明还提供了用于治疗这些白血病的化合物和鉴定抗白血病药的方法。

3. 发明申请

WO2012074960A3 FTY720-DERIVED ANTICANCER AGENTS 审中-公开
标题翻译： FTY720衍生的反应剂
公开(公告)号：WO2012074960A3
公开(公告)日：2012-11-08
申请号：PCT/US2011062304
申请日：2011-11-29
申请人： UNIV OHIO STATE RES FOUND , CHEN CHING-SHIH , KULP SAMUEL K , WANG DASHENG , BYRD JOHN C , MUTHUSAMY NATARAJAN
发明人： CHEN CHING-SHIH , KULP SAMUEL K , WANG DASHENG , BYRD JOHN C , MUTHUSAMY NATARAJAN
IPC分类号： C07C217/30 , A61K31/138 , A61P35/00 , C07C215/30
CPC分类号： C07C217/74 , C07C217/64 , C07C2601/02
摘要： A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula (I) wherein R1 is independently selected from the group consisting of hydrogen, methyl, methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
摘要翻译：描述了许多具有抗肿瘤活性的衍生自FTY720的化合物。这些化合物包括其中R 1独立地选自氢，甲基，甲氧基和羟基的式（I）化合物; R2独立地选自氢，甲氧基和羟基; R3独立地选自烷基和环烷基; 并且n独立地选自0至6.由于不被鞘氨醇激酶2磷酸化，所述化合物具有较低的免疫抑制副作用。

4. 发明申请

WO2004042032A3 CYTOGENETIC ABNORMALITIES THAT ARE PREDICTIVE OF RESPONSE TO THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
标题翻译：对慢性淋巴细胞白血病治疗有反应的细胞因子异常
公开(公告)号：WO2004042032A3
公开(公告)日：2005-07-07
申请号：PCT/US0335225
申请日：2003-11-03
申请人： UNIV OHIO STATE RES FOUND , BYRD JOHN C , HEEREMA NYLA A
发明人： BYRD JOHN C , HEEREMA NYLA A
IPC分类号： C12Q1/68 , G01N33/574 , C07H21/00
CPC分类号： C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.1) have been shown not to be responsive to rituximab, but are responsive to agents that bind CD52, such as alemtuzumab. By customizing treatment of CLL based on a patient's cytogenetic profile, a improved outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.
摘要翻译：提供方法和试剂盒，用于预测B细胞慢性淋巴细胞性白血病（CLL）患者对结合B淋巴细胞表面CD20和CD52抗原的药物的治疗反应。本发明的方法是通过分析从患者获得的细胞的基因组中鉴定特异性染色体异常的存在，包括del（17p13.1）和 del（13q14.3），del（11q22.3）和三体性12中的一种或多种。该方法使用适当的细胞遗传学分析技术进行，例如荧光原位杂交（FISH），具有能够检测特异性细胞遗传学异常的探针。没有del（17p13.1）但del（13q14.3），del（11q22.3）或染色体12的三体性的患者已被证明对结合CD20的药物如利妥昔单抗有反应。已证实del（17p13.1）患者对利妥昔单抗不敏感，但对结合CD52的药物（如阿仑单抗）有反应。通过根据患者的细胞遗传学特征定制CLL的治疗，可以为患者实现改善的结果，同时通过前述不必要的治疗提供的时间和成本节省。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式